Human parvovirus B19 infection with GvHD-like erythema in two allogeneic stem cell transplant recipients

Muetherig, Anke; Christopeit, Maximilian; Müller, Lutz; Grothe, Wilfried; Weber, Thomas; Theurich, Sebastian; Behre, Gerhard

doi:10.1038/sj.bmt.1705589

Cited by 17 publications

(17 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…10,57 B19V exanthema can also mimic cutaneous acute GVHD (aGVHD). 12,60 In our study none of the patients with B19V viremia had any specific signs or suspicion of B19V infection. Neither retrospectively did any clinical manifestation (including anemia) correlate significantly with the B19V viremia.…”

Section: Discussionmentioning

confidence: 96%

“…Allogeneic HSCT patients are at a particular risk for B19V infection, which may lead to severe, persistent and usually nonspecific illness. [10][11][12][13] A few studies address the incidence and clinical spectrum of B19V infections among HSCT patients; however, large prospective studies among the pediatric population are lacking. B19V infections can be severe after allogeneic HSCT and in addition to aplastic crises 14 cause pneumonia 10 and multiorgan failure.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Human parvoviruses B19, PARV4 and bocavirus in pediatric patients with allogeneic hematopoietic SCT

Rahiala

Koskenvuo

Norja

et al. 2013

Bone Marrow Transplant

View full text Add to dashboard Cite

Among the immunocompetent, infections with parvovirus B19 (B19V) and human bocavirus (HBoV) 1 range clinically from asymptomatic to severe, while following allogeneic hematopoietic SCT (HSCT) B19V can cause a persistent severe illness. The epidemiology and clinical impact of HBoV1 and the other emerging parvovirus 4 (PARV4) among immunocompromised patients have not been established. To determine the occurrence and clinical spectrum of B19V, PARV4 and HBoV1 infections, we performed a longitudinal molecular surveillance among 53 allogeneic HSCT recipients for pre-and post-HSCT DNAemias of these parvoviruses. Quantitative real-time PCR showed B19V DNA in sera of 16 (30%) patients, at mean levels of 4.6 Â 10 3 , 9.9 Â 10 7 , 1.1 Â 10 10 and 1.6 Â 10 2 B19V DNA copies/mL pre-HSCT (9/53), and at 1 (6/53), 2 (4/53) and 3 months (1/25) post HSCT, respectively. However, no clinical manifestation correlated with the presence of B19V viremia. All B19V sequences were of genotype 1. None of the sera investigated contained PARV4 or HBoV1 DNAs. Our data demonstrate B19V viremia to be frequent among pediatric allogeneic HSCT recipients, yet without apparent clinical correlates. PARV4 or HBoV1 viremias were not seen in these immunocompromised patients.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Introductionmentioning

confidence: 99%

Human parvoviruses B19, PARV4 and bocavirus in pediatric patients with allogeneic hematopoietic SCT

Rahiala

Koskenvuo

Norja

et al. 2013

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…To our knowledge, nothing is known about parvovirus B19 antigens that induce T‐lymphocytes to cross react with epithelial structures. Yet an increased prevalence of parvovirus B19 DNA in the skin of patients suffering from systemic sclerosis (2), a disease resembling (cutaneous) GvH, and the data published before (1) and here, leaves room for speculation about parvovirus B19 being one possible trigger for aGvH. Future observations should include routine monitoring for parvovirus B19 in biopsies of skin, gut, liver and peripheral blood in the course of the disease.…”

mentioning

confidence: 75%

Parvovirus B19 infection as trigger of graft vs. host disease

Behre

Christopeit

2008

European J of Haematology

View full text Add to dashboard Cite

“…Both may increase the risk of developing other viral infections. Parvovirus B19, which classically produces a "slapped cheek" exanthem, caused a generalized GVHD-like erythema in two allogeneic stem cell transplant recipients [ 29 ].…”

Section: Viral Skin and Soft Tissue Infectionsmentioning

confidence: 99%

Skin and soft tissue infections in the transplant population

Kotton

2008

Curr Infect Dis Rep

View full text Add to dashboard Cite

Solid organ and hematopoietic stem cell transplant recipients are more likely to develop skin and soft tissue infections, which may be caused by common or atypical pathogens. Skin and soft tissue anatomic abnormalities may act as portals of entry for infection, and may result from surgery, venous access, immunosuppressive medications, and other etiologies. Systemic infection may sometimes be recognized by investigation of skin manifestations. Many noninfectious processes of the skin and soft tissues can mimic infection, complicating the diagnosis. Prompt dermatologic consultation and skin biopsy are essential in this vulnerable population. Treatment of infection in transplant recipients may necessitate reduction of immunosuppression, in addition to other adjunctive therapies. Interesting and important new findings about skin and soft tissue infections in transplant recipients are the focus of this review.

show abstract

Human parvovirus B19 infection with GvHD-like erythema in two allogeneic stem cell transplant recipients

Cited by 17 publications

References 8 publications

Human parvoviruses B19, PARV4 and bocavirus in pediatric patients with allogeneic hematopoietic SCT

Human parvoviruses B19, PARV4 and bocavirus in pediatric patients with allogeneic hematopoietic SCT

Parvovirus B19 infection as trigger of graft vs. host disease

Skin and soft tissue infections in the transplant population

Contact Info

Product

Resources

About